Cargando…

Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus

INTRODUCTION: Fibroblast growth factor (FGF) 21 is an important regulator of glycemic control, but the association between circulating FGF21 and diabetic complications is poorly understood. Moreover, basal FGF21 secretion, especially in response to insulin dose, in patients with type 1 diabetes mell...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hirokazu, Nirengi, Shinsuke, Ishihara, Kengo, Sakane, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863253/
https://www.ncbi.nlm.nih.gov/pubmed/35192641
http://dx.doi.org/10.1371/journal.pone.0263774
_version_ 1784655199129829376
author Taniguchi, Hirokazu
Nirengi, Shinsuke
Ishihara, Kengo
Sakane, Naoki
author_facet Taniguchi, Hirokazu
Nirengi, Shinsuke
Ishihara, Kengo
Sakane, Naoki
author_sort Taniguchi, Hirokazu
collection PubMed
description INTRODUCTION: Fibroblast growth factor (FGF) 21 is an important regulator of glycemic control, but the association between circulating FGF21 and diabetic complications is poorly understood. Moreover, basal FGF21 secretion, especially in response to insulin dose, in patients with type 1 diabetes mellitus (T1DM), has not been well examined. Therefore, this study aimed to determine the association of circulating FGF21 levels with diabetic complications and insulin dosage in middle-aged and elderly patients with T1DM. MATERIALS AND METHODS: A total of 127 middle-aged and elderly patients with T1DM, including 68 patients with diabetic complications, and 106 non-diabetic individuals were analyzed in this cross-sectional study. Information on demographic characteristics and T1DM was extracted from their electronic medical records. Serum FGF21 levels were determined using ELISA. RESULTS: Serum FGF21 levels were significantly lower in T1DM patients (75.2 [37.4–135.1] pg/mL) than in non-diabetic participants (151.6 [92.0–224.6] pg/mL; P < 0.001). No diabetic complications were associated with serum FGF21 concentrations. Both basal and bolus insulin doses were significantly and positively correlated with serum FGF21 levels (P < 0.05). Stepwise multiple regression analysis showed that FGF21 level was associated with age and body mass index (P < 0.05), while the basal insulin dose was an independent positive predictor of serum FGF21 levels (β = 0.197, P = 0.032). CONCLUSIONS: Circulating FGF21 levels are reduced in patients with T1DM; however, they are not associated with diabetic complications. In addition, aging, obesity, and insulin dosage are positive determinants of circulating FGF21.
format Online
Article
Text
id pubmed-8863253
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-88632532022-02-23 Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus Taniguchi, Hirokazu Nirengi, Shinsuke Ishihara, Kengo Sakane, Naoki PLoS One Research Article INTRODUCTION: Fibroblast growth factor (FGF) 21 is an important regulator of glycemic control, but the association between circulating FGF21 and diabetic complications is poorly understood. Moreover, basal FGF21 secretion, especially in response to insulin dose, in patients with type 1 diabetes mellitus (T1DM), has not been well examined. Therefore, this study aimed to determine the association of circulating FGF21 levels with diabetic complications and insulin dosage in middle-aged and elderly patients with T1DM. MATERIALS AND METHODS: A total of 127 middle-aged and elderly patients with T1DM, including 68 patients with diabetic complications, and 106 non-diabetic individuals were analyzed in this cross-sectional study. Information on demographic characteristics and T1DM was extracted from their electronic medical records. Serum FGF21 levels were determined using ELISA. RESULTS: Serum FGF21 levels were significantly lower in T1DM patients (75.2 [37.4–135.1] pg/mL) than in non-diabetic participants (151.6 [92.0–224.6] pg/mL; P < 0.001). No diabetic complications were associated with serum FGF21 concentrations. Both basal and bolus insulin doses were significantly and positively correlated with serum FGF21 levels (P < 0.05). Stepwise multiple regression analysis showed that FGF21 level was associated with age and body mass index (P < 0.05), while the basal insulin dose was an independent positive predictor of serum FGF21 levels (β = 0.197, P = 0.032). CONCLUSIONS: Circulating FGF21 levels are reduced in patients with T1DM; however, they are not associated with diabetic complications. In addition, aging, obesity, and insulin dosage are positive determinants of circulating FGF21. Public Library of Science 2022-02-22 /pmc/articles/PMC8863253/ /pubmed/35192641 http://dx.doi.org/10.1371/journal.pone.0263774 Text en © 2022 Taniguchi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Taniguchi, Hirokazu
Nirengi, Shinsuke
Ishihara, Kengo
Sakane, Naoki
Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
title Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
title_full Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
title_fullStr Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
title_full_unstemmed Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
title_short Association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
title_sort association of serum fibroblast growth factor 21 with diabetic complications and insulin dose in patients with type 1 diabetes mellitus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863253/
https://www.ncbi.nlm.nih.gov/pubmed/35192641
http://dx.doi.org/10.1371/journal.pone.0263774
work_keys_str_mv AT taniguchihirokazu associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus
AT nirengishinsuke associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus
AT ishiharakengo associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus
AT sakanenaoki associationofserumfibroblastgrowthfactor21withdiabeticcomplicationsandinsulindoseinpatientswithtype1diabetesmellitus